Bonnie Korytkowski, DO
Family Medicine · Appleton, WINPI 1093211211
Payments from drug & device makers
Across 103 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$422
- Pfizer$210
- Lilly USA, LLC$146
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Novo Nordisk$124
- Amgen$120
- plus $709 from 16 others
What the payments were for
- Food & beverage$1,856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $422 |
| Pfizer | 11 | $210 |
| Lilly USA, LLC | 9 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $125 |
| Novo Nordisk | 7 | $124 |
| Amgen | 7 | $120 |
| Exact Sciences | 6 | $111 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Merck | 4 | $76 |
| AstraZeneca(2 entities) | 4 | $65 |
| Sanofi Pasteur Inc. | 2 | $58 |
| GSK | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Bayer | 2 | $28 |
| Dexcom, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Abbott | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$1,856 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $43,020 |
| JardianceEmpagliflozin | 21 | $30,382 |
| OzempicSemaglutide | 21 | $28,029 |
| FarxigaDapagliflozin Propanediol | 21 | $27,365 |
| MounjaroTirzepatide | 22 | $22,263 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 49 | $15,106 |
| MyrbetriqMirabegron | 13 | $12,596 |
| CreonLipase/Protease/Amylase | 12 | $9,123 |
| VascepaIcosapent Ethyl | 13 | $7,455 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,367 |
| Repatha SureclickEvolocumab | 11 | $7,024 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,773 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 25 | $5,557 |
| JanuviaSitagliptin Phosphate | 14 | $3,665 |
| Atorvastatin Calcium | 301 | $3,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $210 | $43,02037 claims |
| Boehringer IngelheimJardiance | $15 | $30,38221 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $48 | $28,03086 claims |
| Novo NordiskOzempic | $124 | $28,02921 claims |
| AstraZenecaFarxiga | $65 | $27,36521 claims |
| Lilly USA, LLCMounjaro | $146 | $22,26322 claims |
| AbbVieCreon, Synthroid | $422 | $10,98434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $125 | $5,77312 claims |
| MerckJanuvia | $76 | $3,66514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Appleton
- Jose DiasAppleton$121K
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
- John LaabsShawano$3.6M
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Jonathan TemteMadison$542K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.